Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts - Wikidata - awgldk - TriplyDB

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

http://www.wikidata.org/entity/Q28379054

about

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.Murine models for experimental therapy of pediatric solid tumors with poor prognosis.Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions Expression of C-terminal deleted p53 isoforms in neuroblastoma.A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.Reducing irinotecan-associated diarrhea in children.Experience with irinotecan for the treatment of malignant glioma No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children.Selecting multimodal therapy for rhabdomyosarcoma.Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes.Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.Expression of erythropoietin and its receptor in neuroblastomas.Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma.Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts.EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.Successful clinical response to irinotecan in desmoplastic round blue cell tumor.Proteomic Analysis of Neuroblastoma-Derived Exosomes: New Insights into a Metastatic Signature.Clinical pharmacology of camptothecins.The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.

P2860

Q26795742-21C2D98C-38A8-4003-BD41-76FDFC3AEF3A Q31002893-4F42FAC7-08A0-4C52-8D63-DE6A5B7FB0F2 Q34210418-19479622-757A-462C-A16E-0E7B90C2C62F Q34281235-20E8ECAD-3F17-4980-A7B0-6B9879968FCE Q34344177-C4D53CBB-83CD-4A36-A27A-40DE0CEDD5A5 Q34679179-A7C67C89-36D5-4AD9-BD48-0C4B715EC216 Q34787772-2560B9A7-0B65-415A-8637-5F7BFF75E197 Q35130560-36924C7D-8411-4698-A094-E6C0010C5CAF Q35597039-0F44E9F3-89B5-4525-8165-E9C3BD30D67D Q35887473-1CD5DCD2-156C-4270-8318-FBA66397C4D4 Q36002340-884D1491-D479-465A-841A-1374AC8293ED Q36618917-F9951CBF-9055-477A-BA7E-84419B89B495 Q36772203-BE869F9A-C21E-4A2E-BA9E-0216DAB9D7E8 Q36849970-D16DCAE6-BC16-4594-957D-1C204D4745B0 Q37265907-9AB8BC31-D26D-40D1-9929-E99F939B1F67 Q37355466-ABB010BD-6677-440F-A08F-D3A2796079AB Q37378223-C5CEB17C-EEF2-4131-9FF1-6372840BA270 Q37621288-7ADCFF45-3710-4401-AA9E-BF1AB7080599 Q37782096-7378DEFA-7943-4782-9F5C-E29BFAF9931E Q38938545-1A4E1659-1589-4E6C-89E5-EAA8B41F7856 Q38997280-B472EBC2-D206-426A-A582-5C1F3CBB13AD Q39143967-4F4E27C6-4FCC-4B77-BB52-980A3667FB1E Q39272645-572598B4-0075-4488-99D2-2534AAC2FBBC Q40103316-52B89EC8-D1C4-46EE-A760-B407C18EBA33 Q41076904-A13312BD-4BA8-4AE0-894E-EDC583FF1692 Q43066520-6720507C-21B4-40DC-B1E0-71AC5AAB7C05 Q43679544-169B0837-44C3-481B-8309-9CC58A9F02CD Q45870066-662F5FD3-378E-44BF-9698-AF226FDE62F2 Q46665992-0482FE49-0B5A-4FF2-BCD9-ED6C6A5AF927 Q46827781-4F96ACDF-4A6F-48B9-82BA-04D447F3659C Q46862627-6CC2428A-3D07-4A23-93B2-30EACAFE082F Q47832898-035512DF-78A4-46C7-A006-0A8FAA0D52FF Q50516173-0AFCF1F9-3D05-4B3A-8469-288E579FD2EF Q50882557-6086A17E-510D-4117-A851-9F2E5DE1F398 Q53780736-DEA374F5-7FFE-4B1D-8740-3167AA5234CB Q54655761-556D75BB-D785-4906-88BA-B476590B3C1D Q55478214-8F95C84F-A4EC-4846-A253-2856F5373AE3

P2860

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

http://www.wikidata.org/entity/Q28379054

description

1996 nî lūn-bûn

@nan

1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@ast

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@en

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@nl

type

label

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@ast

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@en

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@nl

prefLabel

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@ast

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@en

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@nl

P1433

Q28379054-925C29DB-38A6-402F-BC3F-45DDF19D64E6

P1476

Q28379054-4B2D0071-66BB-4C7A-BC74-5BA2B620990F

P2093

Q28379054-07B6CC50-09C4-4561-A605-DEDD91C9307A

Q28379054-1B7304B7-9200-4D65-B410-1805053588C8

Q28379054-1C60502A-4A5B-4094-B69C-F575EA11D281

Q28379054-1FD7D187-1FCF-4B12-B7AB-FC3200AF92D6

Q28379054-341B642C-B7B0-4C7B-91EF-FA8B7F59BAD0

Q28379054-6749A227-463F-4E7A-910D-6BDFC4F52EE7

Q28379054-A4B3C32A-0800-4C06-8ABF-05D3CC17B8E7

Q28379054-AC8615D8-5567-45CA-A64C-D2A7F55B2895

Q28379054-C5888678-8939-4A74-AB27-BFDA6C32D390

Q28379054-EEAE932D-8B09-430A-BA69-1627CADD6460

P2860

Q28379054-04F5DAEC-F8B9-49E9-BA83-CE88078A6671

Q28379054-1965C59B-A64A-4F94-9C43-AF4AB469FECC

Q28379054-267BBAEE-CFE1-4617-84F0-2A09C15EF61E

Q28379054-32EF65C6-1AF2-40D3-BE89-CF83594EED07

Q28379054-3857D55C-AFCC-413F-95F9-6CAB44BF124E

Q28379054-4368F9BE-F8B6-40D5-97CB-7ACC7C83ED56

Q28379054-4407167B-7107-4B6C-A887-68B4BCA090EF

Q28379054-4B39DE22-2E19-4E4D-A623-93F9EEE8F52B

Q28379054-556824B8-AF2C-413A-99F0-C3CBB86201D4

Q28379054-61AA37F8-E086-4E9B-B307-934D254703B3

P2888

Q28379054-4E8D4840-F255-44ED-A314-6ACB971689E5

P304

Q28379054-86282EF6-2F0D-477F-A120-382BA6EFBB17

P31

Q28379054-A77CA438-4EEE-4371-A39F-B7D30197D8C6

P356

Q28379054-1BD96F97-46D6-4AAD-81A7-92C6A5DB3BD4

P407

Q28379054-77BCDECA-0EEC-4C4A-934E-7EC9A1426555

P433

Q28379054-4CA1471C-652C-46A1-9EAD-E3D8314C6FAF

P478

Q28379054-0A155EC3-BD4A-4A81-BCF0-CD0B708B0D62

P577

Q28379054-5414CA64-3305-4A0F-8CBB-B6B26CAAB35E

P5875

Q28379054-B4A4E4B9-988D-45EF-8CC3-DAF77F6B971F

P6179

Q28379054-06A6D8B2-61EE-45BC-A5F8-73A720F103D6

P698

Q28379054-C338BE3A-0E19-4BA4-9763-5FD22AF2913C

P921

Q28379054-DF1E2E41-DB32-4886-8017-DA0E58E119B2

P932

Q28379054-DBBBA6F1-3A95-4080-A43D-BDBB800F23ED

P356

P1433

British Journal of Cancer

P1476

Therapeutic activity of CPT-11 ...... r and neuroblastoma xenografts

@en

P2093

A Gouyette

http://www.w3.org/2001/XMLSchema#string

A M Vénuat

http://www.w3.org/2001/XMLSchema#string

B Bressac-de-Paillerets

http://www.w3.org/2001/XMLSchema#string

F Gyergyay

http://www.w3.org/2001/XMLSchema#string

G Vassal

http://www.w3.org/2001/XMLSchema#string

I Boland

http://www.w3.org/2001/XMLSchema#string

J Bénard

http://www.w3.org/2001/XMLSchema#string

J Morizet

http://www.w3.org/2001/XMLSchema#string

M C Bissery

http://www.w3.org/2001/XMLSchema#string

M J Terrier-Lacombe

http://www.w3.org/2001/XMLSchema#string

P2860

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.

Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification.

Camptothecins: from bench research to hospital wards.

Mechanisms of topoisomerase I inhibition by anticancer drugs.

A functional analysis of tumor suppressor activity for peripheral neuroepitheliomas by monochromosome transfer.

Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.

P2888

P304

537-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1996.398

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

1996-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14442057

http://www.w3.org/2001/XMLSchema#string

P6179

1013192113

http://www.w3.org/2001/XMLSchema#string

P698

8761367

http://www.w3.org/2001/XMLSchema#string

P921

P932

2074686

http://www.w3.org/2001/XMLSchema#string